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Opinion statement
Survival rates of childhood cancer have improved markedly, and today more than 80 %
of those diagnosed with a pediatric malignancy will become 5-year survivors. Never-
theless, survivors exposed to cranial radiotherapy (CRT) are at particularly high risk
for long-term morbidity, such as endocrine insufficiencies, metabolic complications,
and cardiovascular morbidity. Deficiencies of one or more anterior pituitary hormones
have been described following therapeutic CRT for primary brain tumors, nasopharyn-
geal tumors, and following prophylactic CRT for childhood acute lymphoblastic leu-
kemia (ALL). Studies have consistently shown a strong correlation between the total
radiation dose and the development of pituitary deficits. Further, age at treatment
and also time since treatment has strong implications on pituitary hormone deficien-
cies. There is evidence that the hypothalamus is more radiosensitive than the
pituitary and is damaged by lower doses of CRT. With doses of CRT G50 Gy, the
primary site of radiation damage is the hypothalamus and this usually causes isolated
GH deficiency (GHD). Higher doses (950 Gy) may produce direct anterior pituitary
damage, which contributes to multiple pituitary deficiencies. The large group of
ALL survivors treated with CRT in the 70–80-ties has now reached adulthood, and
these survivors were treated mainly with 24 Gy, and the vast majority of these
patients suffer from GHD. Further, after long-term follow-up, insufficiencies in pro-
lactin (PRL) and thyroid stimulating hormone (TSH) have also been reported and a
proportion of these patients were also adrenocoticotrophic hormone (ACTH) deficient.
CRT to the hypothalamus causes neuroendocrine dysfunction, which means that the
choice of GH test is crucial for the diagnosis of GHD.
Introduction
Survival rates of childhood cancer have improved
markedly, and today more than 80 % of those
diagnosed with a pediatric malignancy will become
5-year survivors [1]. In the 1970s and early 1980s,
cranial radiotherapy (CRT) has been part of an
effective multimodality therapy to treat as well as
prevent the spread of childhood acute lymphoblas-
tic leukemia (ALL). Although radiotherapy was ef-
fective, survivors exposed to CRT are at particularly
high risk for long-term morbidity, such as endo-
crine insufficiencies, second malignant neoplasms,
metabolic complications, and cardiovascular mor-
bidity [2]. The use of radiotherapy to treat ALL
has been reduced to avoid the late occurring com-
plications, but 10–15 % of the contemporary ALL
patients will still be exposed [3]. The most com-
monly diagnosed chronic conditions after CRT in-
volves the endocrine system and in particular the
hypothalamic-pituitary-axis [4••, 5•]. Deficiencies
of one or more anterior pituitary hormones have
been described following therapeutic CRT for pri-
mary brain tumors, nasopharyngeal tumors, and
following prophylactic CRT for childhood ALL.
Studies have consistently shown a strong positive
correlation between the total radiation dose and
the development of pituitary deficits [6–8]. Further,
age at treatment and also time since treatment has
strong implications on pituitary hormone deficien-
cies [9]. It has become apparent that the pituitary
hormone deficiencies can develop many years after
radiotherapy, and studies have suggested that the
damage might be at the level of hypothalamus [10,
11]. There is a difference in the incidence of ante-
rior pituitary hormone deficiencies, with secretion
of growth hormone (GH) being the most frequent-
ly affected followed by gonadotropin, adrenocorti-
cotrophic hormone (ACTH) and, thyroid stimulat-
ing hormone (TSH). Prolactin (PRL) insufficiency is
probably an early occurring insufficiency. The most
important predictive factors to deficient hormone
axes are dose of CRT, age at CRT, and time since
CRT.
Hypopituitarism is an important diagnosis to
make correctly, and endocrinologists should be in-
volved at an early stage of patient management. It
has been shown that untreated pituitary deficiency
is associated with poor health. Hypopituitary pa-
tients on conventional hormone therapy but with-
out GH therapy have an increased cardiovascular
mortality in comparison with the general popula-
tion [12]. GH is secreted in an intermittent pulsa-
tile pattern from the pituitary and is under control
of two interacting hypothalamic factors—one stim-
ulatory, growth hormone releasing hormone
(GHRH), and the other inhibitory, somatostatin.
GH secretion is regulated by negative feedback by
circulating insulin growth factor-I (IGF-I). GH acts
on several organs and tissues in the body such as
the brain, muscle, kidney, heart, and bone. There
are currently consensus guidelines on the diagnos-
tic procedures of GH deficiency published in 2000
by The Growth Hormone Research Society. Lutein-
izing hormone (LH) and follicle stimulating hor-
mone (FSH), essential for reproduction, are secret-
ed from cells in the pituitary called gonadotrophs
and stimulates the gonads in both women and
men. The secretion of PRL from the pituitary is
inhibited by dopamine and stimulated by thyroid
releasing hormone (TRH) from the hypothalamus.
TSH secretion is regulated by the interplay of hy-
pothalamic factors TRH and somatostatin and thy-
roid feedback. The regulator of TSH secretion is
feedback by thyroid hormones T4 and T3. Thyroid
hormones act at the hypothalamic level to inhibit
TRH synthesis and at the pituitary to inhibit TSH
secretion. ACTH secretion by the pituitary is regu-
lated by corticoreleasing hormone from the hypo-
thalamus. ACTH stimulates the adrenal cortex to
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release cortisol, a life sustaining hormone essential
to the maintenance of homeostasis.
The aim of this review is to provide an overview
of late hypothalamus-pituitary dysfunction due to
cranial radiotherapy in adult survivors of childhood
leukemia. We summarize the range of anterior pi-
tuitary hormone deficiencies, such as GH, LH, FSH,
PRL, ACTH, and TSH, and provide recommenda-
tions for diagnosis and surveillance for childhood
leukemia survivors.
Acute lymphoblastic leukemia
Acute lymphoblastic leukemia is the most common type of childhood
cancer and is usually treated with chemotherapy such as anthracyclines,
vinicristine, asparaginase, and corticosteroids. Further, patients with
central nervous system leukemia receive cranial radiotherapy. Impor-
tantly, the history of the ALL survivors treated during the 1970s and
early 1980s mirrors how to follow these survivors today. Cranial radio-
therapy (CRT) was a crucial part of an effective multimodality therapy to
treat as well as prevent the spread of childhood acute lymphoblastic
leukemia (ALL), which means that everyone diagnosed with ALL during
these years received CRT (18–24 Gy) or craniospinal radiotherapy (CSR).
Total body irradiation (TBI) has been used since the 1980s in prepara-
tion for bone marrow transplantation for relapsed leukemia. Thus, ALL
survivors treated with CRT, CSR, or TBI and with any of the following
symptoms should be referred for endocrine evaluation: persistent fatigue,
obesity, abnormal menstruation, sexual dysfunction, and fragility
fractures.
GH deficiency
CRT is a potent cause of hypopituitarism, and the severity is related to
dose, the fraction schedule, and the post-irradiation time interval [11,
13]. CRT will affect the hypothalamus, which is more sensitive to
irradiation than is the anterior pituitary [6, 14] and GH deficiency
(GHD) is usually the first and often the only established endocrine
sequel of CRT [11, 15]. CRT in children frequently causes abnormal
hypothalamic-pituitary function later in life [6], and growth deficits have
been reported consistently after doses of 9 4 Gy CRT [16–18]. However,
GHD has also been shown during childhood in ALL patients after low
doses of G20 Gy [19, 20], but these data are less consistent [21, 22].
Based on the background to hypothalamic-pituitary disease, different
GH tests must be carefully considered [23]. There are clear cut off levels
for GH when a GHD is diagnosed, i.e., for the insulin tolerance test
(ITT) the level is GH G3 ug/l (or 9 mU/L), and for the growth-hormone
releasing hormone (GHRH)-arginine test which is BMI dependent, we
used the same cut off levels [24]. Thus, in accordance with Darzy et al.
[23], Björk et al. [24] also recorded that the ITT clearly reflected the
presence of early radiation-induced GHD, but this was not always the
case with the GHRH-arginine test, which more confirmed the diagnosis
later in life. The GHRH-arginine test is more a stimulation test directly
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on the pituitary, reflecting the pituitary GH secretion. However, when
the GH response to GHRH-arginine was low, we considered the patient
to be clearly GHD [24]. Thus, it would appear that primarily the
hypothalamus and then later direct pituitary damage from CRT was the
cause of GHD among the former ALL patients.
Brennan et al. [20] investigated GH secretion after CRT in 32 adults,
6.8–28.6 (median 17.8 years) years since CRT. Nine of the patients were
severely GHD (peak GH response G9 mU/l to both provocative agents
arginine or ITT), and a further 12 patients were GH insufficient (peak
GH response G20 mU/l to both tests with at least one peak GH
response 99 mU/l). They had all received between 18–24 Gy. A group of
44 childhood ALL with a median of 25 years [19–32] of whom all were
treated with CRT median 24 Gy (range 18–24 Gy) were investigated.
They were treated with CRT at a median age of 5 years (range 1–18),
and 17 years had passed since ALL treatment and CRT [9]. According to
the ITT and or the GHRH-arginine test, 91 % were considered GHD. All
patients with a peak GH 3.9 μg or more on the GHRH-arginine test
performed an ITT (Fig. 1).
Among 310 childhood cancer survivors, of whom 34.5 % were for-
mer ALL survivors, the most frequent hormone deficiency was gonadal,
primary hypothyroidism and GHD [5•]. GHD was evaluated using
standard GH tests. GHD was found among 16.13 %, where of the most
frequent background diagnosis was brain tumors, followed by hemato-
logical malignancies.
In a recent paper from Chemaitilly et al. [4••] on a mixed popula-
tion of adults with childhood cancer, with 72 % leukemia diagnosis,
about 46.5 % were diagnosed with GHD. However, GHD was defined
Fig. 1. Receiver operating characteristic curve of the GHRH-arginine test for classifying severe GHD, defined as ITT below 3 μg/L.
The combination of sensitivity and specificity of the peak GH cut off level of 9 μg/L is marked with filled circle. Note that the
specificity-axis is labeled in descending order.
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only as a measurement of morning serum IGF-I G−2.0 z-score. This is
probably a strong underestimation as serum IGF-I is not considered
sufficient to set the diagnosis of GHD [25–27].
Gonadotropin deficiency
Gonadotropin deficiency in childhood cancer survivors is most frequent after a
radiation dose to the hypothalamus-pituitary axis of 940Gy [28, 29] and can be
presented with a spectrum from subclinical to severe impairment. It is the
second most common anterior pituitary hormone deficiency after CRT. Clini-
cally significant gonadotropin deficiency after CRT is often apparent after long-
term follow-up with an incidence of 20–50 % [6, 30, 31].
Chemaitilly et al. [4••] investigated a mixed population of adults treated for
childhood cancer of which 72%were ALL survivors. LH and FSH deficiency was
recognized in 10.8 % of the total cohort of survivors 27 years after cancer
diagnosis. The definition of LH/FSH deficiency in men was a testosterone less
than 200 ng/dL (10 nmol/L) including a LH less than 7 IU/L and FSH less than
9.2 IU/L. For the women, the definition was amenorrhea in women less than
40 years old with an estradiol less than 17 pg/ml and FSH less than 11.2 IU/L.
After CRT doses more than 40 Gy, the prevalence of LH and FSH deficiency was
22.7 and 7.8 % after CRT doses of less than 40 Gy [4••]. Male sex, CRT dose
922 Gy and BMI 930 kg/m were associated with higher odds of LH and FSH
deficiency. Results from a recent study, only including men, of 199 childhood
cancer survivors showed that 13 survivors had central hypogonadism 14 years
after cancer diagnosis. Survivors with testosterone less than 3 ng/dL were
considered to have hypogonadism [5]. The risk of hypogonadismwas higher in
survivors treated with CRT. ALL survivors treated with a moderate dose of CRT
of 18–24 Gy have an increased risk of precocious puberty [31, 32]. On the other
hand, a large study of 949 female ALL survivors found craniospinal radiother-
apy to be associated with an increased risk of late onset menarche [33]. Thus,
both early and delayed puberty can be seen.
PRL deficiency
Hyperprolactinemia after treatment with CRT for childhood cancer has been
reported in studies investigating children treated with a dose 940 Gy after a
short follow-up [6, 34]. The hyperprolactinemia is due to the reduction in the
neurotransmitter dopaminewhich has an inhibitory effect on PRL secretion.On
the other hand, hypoprolactinemia has also been recorded in ALL survivors
after CRT, but after long-term follow-up [35]. It has been suggested that severe
PRL deficiency occurs late after all other anterior pituitary insufficiencies in the
evolution of hypopituitarism and that very low levels of PRL are related to the
severity of hypopituitarism [36]. Littley et al. [11] showed that after CRT to
adults basal PRL showed an early rise, followed by a gradual decline after a few
years. CRT seems to cause a primarily diminished inhibition of PRL secretion
resulting in increased basal PRL levels, followed by a slowly developing
lactotroph dysfunction. In contrast, in rats exposed to non-fractionated CRT,
GH and PRL were shown to be most sensitive of all pituitary hormones, with a
dramatic decrease with time and dose after irradiation [37]. It has been shown
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that PRL deficiency, thus very low PRL levels, was independently associated
with reduced levels of serum IGF-I in severely GHD adults and that PRL
deficiency can act as a surrogate marker for the severity of GHD [36]. Dunkel
et al. found normal basal but subnormal PRL response after metoclopramide in
ALL children treated with CRT [38]. Follin et al. recorded significantly lower
basal PRL levels and PRL area under the curve (AUC) after GHRH-arginine
stimulation test in 44 ALL survivors compared to matched controls of both
gender [35]. Seven ALL women reported pregnancies during follow-up, and six
out of seven women reported failure to lactate. Thus, ALL patients treated with
CRT were not only GH deficient but also PRL insufficient 20 years [8–27] after
diagnosis [35].
TSH deficiency
There are conflicting results in early studies, with no risk [39] or an
increased risk [40, 41] of central hypothyroidism after CRT in ALL
children treated with G30 Gy. Some previous studies have, however,
limitations with a short follow-up period, of 6–9 years [36, 37] and the
use of self-reported thyroid function [36]. After a follow-up of an
average of 6 years after ALL treatment, one out of the 33 children was
found to have a papillary carcinoma of the thyroid. Thyroid function
was normal in all patients, with the exception of one case which showed
high basal levels TSH (9.2 microU/mL) levels, but normal response to
TRH (TSH = 17.8 microU/mL). This hormonal alteration was later nor-
malized [40]. In a study with 8 years of follow-up of survivors of
childhood ALL treated with prophylactic CRT, no adverse effect on
hypothalamo-pituitary-thyroid function was recorded [41].
Hypothalamic-pituitary-thyroid dysregulation after CRT, identified by
a TRH-stimulation test or TSH surge, has been recognized in as many as
15 % of former ALL patients 10 years after CRT [33]. In a recent study
from Follin et al. [35] with a median of 20 years of follow-up, no
significant difference in basal TSH and only slight disparity of free T4
levels (higher), which indicates no known clinical significance, was
shown. However, a slightly lower TSH response to a TRH test, shown in
13 ALL patients, might be an early indication of TSH dysfunction. This
is in contrast to Darzy et al. [23] who, 11.5 years after cancer treatment
(with mixed diagnosis), found increased TRH-stimulated TSH levels in
cranially irradiated patients with GHD as compared to matched controls.
Disparity in results may be due to differences in radiation dose, type of
cancer (34 patients treated for brain tumors and 3 for ALL), age at
cancer diagnosis, and particularly in follow-up-time. GH, and thus GHD,
plays a role in the regulation of thyroid hormone metabolism, with
both a central effect, with an increase in somatostatin inhibition of TSH
secretion [42], and a peripheral effect with an increased conversion of
free T4 to free T3.
In another study of 310 childhood cancer survivors (CCS), of whom
34.5 % were former ALL survivors, the most frequent hormone defi-
ciency was gonadal, primary hypothyroidism, and GHD, after a median
time of 16 years since diagnosis [5•]. They documented at least one
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endocrine disease among 50 % of CCS. Primary hypothyroidism was
diagnosed among 17.7 %, whereas seven patients had central hypothy-
roidism.
Chemaitilly et al. [4••] investigated a mixed population of adults
with childhood cancer with a mean of 27 years (10–48) after treatment,
with 72 % leukemia patients. TSH deficiency was defined as G4.0 mIU/L
and a FT4 G0.9 ng/dL (11 nmol/L). No TRH test was performed. With
these baseline results, 7.5 % were considered TSH deficient [4••].
ACTH deficiency
Symptoms of ACTH deficiency is often subtle such as poor weight gain,
anorexia, and fatigue and should be separate from primary adrenal
insufficiency presenting with electrolyte imbalance, vitiligo, and hyper-
pigmentation. Clinically apparent ACTH deficiency is uncommon after
CRT. After a total radiation dose of G50 Gy to the H-P axis, around 3 %
of childhood brain tumor survivors present with ACTH deficiency short
time after (3–10 years) after diagnosis [6, 34]. After radiation doses of
950 Gy the frequency of ACTH deficiency is significantly increased in
survivors with head and neck tumors with rates of 27–35 % up to
15 years after treatment [13, 43]. In a study including 310 CCS with
mainly hematological malignancies, the authors found four survivors
with central hypoadrenalism. Among the 310 survivors, 74 were treated
with CRT in childhood. The survivors were screened with morning
cortisol, and ACTH and if they were presented with abnormal levels they
were tested with proper stimulation tests [5•]. Chemaitilly et al. (year)
investigated a mixed population of 748 CCS 27 years after CRT and of
which 72 % were ALL survivors. The definition of ACTH deficiency was
a cortisol G5 μg/dl (135 nmol/L), and the prevalence of ACTH defi-
ciency in this population was 3.9 % [4••].
In a homogenous group of ALL survivors, treated with a moderate
dose of CRT (18–24 Gy), Follin et al. report ACTH insufficiency [44].
Fourteen out of 37 (38 %) ALL survivors had a subnormal cortisol
response to an insulin tolerance test (ITT) (257–478 nmol/L; normal
9500 nmol/L) while there was no significant difference in basal cortisol
levels between 44 ALL survivors and healthy matched control subjects.
ALL women, but not ALL men, had significantly lower ACTH levels
compared to gender matched controls. However, only a few survivors
needed regular hydrocortisone replacement.
Conclusion
CRT is a potent cause of hypopituitarism, and the severity is related to
dose, the fraction schedule, and the post-irradiation time interval.
Childhood ALL survivors treated with CRT often develop dysfunction of
the hypothalamic-pituitary axis with a spectrum of hormone deficiencies
that develop over several years. As GH is the most sensitive hormone to
CRT, followed by gonadal, PRL, adrenal, and thyroid, the vast majority
of ALL survivors suffer from GHD. The hypothalamus is more sensitive
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to CRT than the pituitary and causes neuroendocrine dysfunction, whichmeans
that the choice of GH test is crucial for the diagnosis of GHD. Further, after long-
term follow-up, insufficiencies in PRL and TSH and also ACTH have been
reported. Life-long surveillance of the entire hypothalamic-pituitary axis is
recommended in ALL survivors treated with CRT.
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